Miller School researchers featured on “Academic Minute” radio show – InventUM
Five researchers from the University of Miami’s Miller School of Medicine represented the school in this week’s takeover of “Academic Minute” – a Northeast-based public radio show with national reach.
Each day, a different Miller School researcher participated in a two-and-a-half-minute discussion of discoveries and advancements, keeping listeners up to date with what’s new and exciting in their fields. Follow the links below to listen to the episodes.
monday august 15
Ranjith Ramasamy, MD, associate professor and director of the Miller School’s reproductive urology program, opened the series with a segment discussing the “impacts of COVID-19 and its vaccines on male fertility.”
Dr. Ramasamy talks about his study, published in the Journal of the American Medical Association, proving that the COVID-19 vaccine does not impact male fertility. His research has shown that the COVID-19 virus can remain in penile tissues long after recovery and cause damage to other organs, underscoring the importance of vaccination.
tuesday august 16
Luanda Grazette, MD, MPH, FACC, professor of medicine at the Miller School and director of advanced heart failure, heart failure recovery, and therapeutic innovation at the University of Miami Health System, talks about “heart failure – no longer a death sentence.” Dr. Grazette explains why heart failure is no longer the fatal diagnosis it once was, and how heart failure patients are now able to fully live their lives and manage their disease, such as diabetic patients.
Dr. Grazette discusses taking an intentional approach to promoting recovery from heart failure and expanding knowledge in the field by measuring the effects and changes associated with recovery. His team also focuses on multidisciplinary collaboration, enabling patients to access the latest FDA-approved therapies and participate in clinical trials of new therapies.
Wednesday August 17
During this segment, James Galvin, MD, MPH, professor of neurology and director of the Miller School’s Comprehensive Center for Brain Health, dives into the “correct diagnosis of dementia with Lewy bodies,” discussing his research on nearly of 1,000 patients, 75% of whom had initially been misdiagnosed.
With 1.4 million Americans suffering from this disease, Dr. Galvin is asking clinicians to use the LBD diagnostic module, which gives providers and researchers better tools to identify the disease in patients. This resource is vital because misdiagnosis is a common problem that can have tragic consequences. Dementia researchers will also benefit, as the module will help them better identify participants and promote new clinical trials. For clinicians, the diagnostic tool will help them provide better care.
Thursday August 18
Christine Dinh, MD, associate professor of otolaryngology, otology, neurotology, and lateral skull base surgery, educates the public on the “National Multicenter Clinical Trial for Neurofibromatosis Type 2.”
Neurofibromatosis type 2 (NF2) is a devastating disease resulting from a genetic mutation that can cause several types of tumors involving the brain, spine and peripheral nerves. The disease can further lead to hearing loss, tinnitus, balance problems and other neurological problems such as paralysis. To better understand and treat the disease, Dr. Dinh will be the principal investigator at the Miller School clinical trial site, where she and her team will examine new drug options to treat four different types of tumors caused by NF2.
friday august 19
The Miller School takeover of the “Academic Minutes” ends with Maria Abreu, MD, Professor of Medicine, Microbiology and Immunology, telling listeners about “Dietary Studies for Patients with IBD and Crohn’s” .
Dr. Abreu talks about his study of patients on diets consisting first of high fat and low fiber, then high fat and high fiber. The results showed that a low-fat diet was correlated with a more significant improvement in the microbiome profiles of IBD patients, a decrease in inflammatory markers and an improvement in quality of life. The study should be repeated on patients with Crohn’s disease.